Small cap REIT Seritage Growth Properties (NYSE: SRG) has elevated short interest of 38.21% according to Highshortinterest.com. Seritage Growth Properties is a publicly-traded, self-administered and self-managed REIT with 230 wholly-owned properties and 23 joint venture properties totaling approximately 40 million square feet of space across 49 states. The Company��s mission is to create and own revitalized shopping, dining, entertainment and mixed-use destinations that provide enriched experiences for consumers and local communities, and create long-term value for our shareholders.
However and pursuant to a master lease, 175 of the Company's wholly-owned properties are leased to Sears Holdings Corp (NASDAQ: SHLD) and are operated under either the Sears or Kmart brand. The master lease provides the Company with the right to recapture certain space from Sears at each property for retenanting or redevelopment purposes. At 83 properties, third-party tenants under direct leases occupy a portion of leasable space alongside Sears and Kmart, and 37 properties are leased only to third parties. The Company also owns 50% interests in 28 properties through JV investments with GGP Inc., Simon Property Group, Inc., and The Macerich Company. A substantial majority of the space at the Company's JV properties is also leased to Sears Holdings under master lease agreements that provide for similar recapture rights as the master lease governing the Company's wholly-owned properties.
Best Small Cap Stocks To Buy For 2019: Athersys, Inc.(ATHX)
Advisors' Opinion:- [By Ethan Ryder]
Media stories about Athersys (NASDAQ:ATHX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Athersys earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.8155037155159 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
- [By Logan Wallace]
Shares of Athersys, Inc. (NASDAQ:ATHX) dropped 10.8% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $2.01 and last traded at $2.06. Approximately 2,886,300 shares were traded during mid-day trading, an increase of 278% from the average daily volume of 763,566 shares. The stock had previously closed at $2.31.
Best Small Cap Stocks To Buy For 2019: Alder BioPharmaceuticals, Inc.(ALDR)
Advisors' Opinion:- [By Ethan Ryder]
Alder Biopharmaceuticals (NASDAQ:ALDR) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday.
- [By Ethan Ryder]
Needham & Company LLC assumed coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report issued on Wednesday. The brokerage issued a buy rating and a $28.00 price objective on the biopharmaceutical company’s stock.
- [By Cory Renauer]
Migraines affect perhaps a billion people the world over, and it's been three decades since they had a new preventative treatment option. That means there could be enough demand to drive�blockbuster sales for a new class of treatments making their way to consumers right now, one of which could come from�little Alder Biopharmaceuticals Inc. (NASDAQ:ALDR).
- [By Stephan Byrd]
BidaskClub cut shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from a strong-buy rating to a buy rating in a report released on Tuesday.
A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective on the stock. Mizuho restated a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Wednesday, March 28th. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Leerink Swann reiterated an outperform rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Alder Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $26.33.
- [By Joseph Griffin]
Mizuho reaffirmed their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Thursday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.
- [By Brian Feroldi]
Shares of Alder Biopharmaceuticals (NASDAQ:ALDR), a clinical-stage biotech focused on migraines, rose as much as 14% in afternoon trading on Friday. The jump was in response to the news that Teva Pharmaceutical Industries (NYSE:TEVA) is scrapping part of a late-stage study of a potential rival to Alder's lead compound eptinezumab. Alder's stock has since cooled off, but was still up about 6% as of 3:58 p.m. EDT.
Best Small Cap Stocks To Buy For 2019: Xerox Corporation(XRX)
Advisors' Opinion:- [By ]
Xerox (XRX) late Sunday terminated its merger with Fujifilm at the same time that it reached a deal to add five Icahn-backed directors onto its board and replace its controversial CEO. It marks a major victory for the insurgent investors at the document technology company's gate.
- [By Douglas A. McIntyre]
Xerox Corp. (NYSE: XRX) has been in deep trouble for years. It did not make the train traveling toward the digital storage and sharing of documents and corporate data. According to rumors in The Wall Street Journal and other media, two large shareholders have begun to pressure the Xerox board to sell the company, which may be the only way Xerox has a viable future.
- [By ]
A New York Judge late Friday issued an order temporarily blocking Xerox Corp.'s (XRX) plan to merge with Fujifilm. At the same time, the judge gave the document technology company's third-largest shareholder permission to move ahead with a change-of-control proxy contest to take over Xerox's board.
- [By ]
Prior to agreeing to a blockbuster deal with Fujifilm, Xerox Corp. (XRX) received an inquiry from HP Inc. (HPQ) , according to people familiar with the situation, though no formal bid was ever launched.
- [By Douglas A. McIntyre]
Xerox Corp. (NYSE: XRX) reversed course and said its CEO would stay after a battle that�cost him his job. According to CNBC:
Xerox Corp said on Thursday its current board and management team, which included Chief Executive Jeff Jacobson, will stay, after a settlement agreement it had reached with dissenting shareholders to oust them expired.
No comments:
Post a Comment